Aktie A061250 HWAIL PHARMACEUTICAL CO.,LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Hwail Pharmaceutical Co.,Ltd.

Aktien

A061250

KR7061250007

A061250

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 17.05.2024 		% 5 Tage % 1. Jan.
1.647 KRW +0,73 % Intraday Chart für Hwail Pharmaceutical Co.,Ltd. +1,17 % -25,31 %
2023 Hwail Pharmaceutical Co.,Ltd. (KOSDAQ:A061250) kündigt einen Aktienrückkauf im Wert von 5.000 Millionen KRW an. CI
2023 Hwail Pharmaceutical Co.,Ltd. genehmigt einen Rückkaufplan. CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.
Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback announced on August 21, 2023, has expired with 2,340,000 shares, representing 3.52% for KRW 4,980.33 million.
Hwail Pharmaceutical Co.,Ltd. announced extension to the offering period
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.
Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 25.999996662 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.
Hwail Pharmaceutical Co.,Ltd.(KOSDAQ:A061250) dropped from S&P Global BMI Index
Hwail Pharmaceutical Co.,Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
Hwail Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.
Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback announced on March 16, 2022, has expired with 1,519,180 shares, representing 2.23% for KRW 4,999.11 million.
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.
Hwail Pharmaceutical Co.,Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
Hwail Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.
Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 5.0000013 billion in funding from Osung Advanced Materials Co., Ltd.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A061250 Aktie
  4. Nachrichten Hwail Pharmaceutical Co.,Ltd.
  5. Andere Sprachen